Lantheus (LNTH)
(Delayed Data from NSDQ)
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
LabCorp Grows on Solid Diagnostics, Currency Woes a Drag
by Zacks Equity Research
Although LabCorp's (LH) Covance drug development business puts up a dull performance, the market is upbeat about its Diagnostics business, which has recently displayed a solid show.
Medtronic (MDT) Sees a Mixed Q1, New Products Bode Well
by Zacks Equity Research
Despite mixed results in Q1, Medtronic (MDT) displayed balanced growth with strength in three of its major business segments.
PetMed Express Focuses on Advertising, Competition Rife
by Zacks Equity Research
PetMed Express (PETS) focuses on advertising to boost new order sales is striving to implement several strategies to revitalize its top line.
Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.
LabCorp & Interpace Extend Deal, Boost Cancer Portfolio
by Zacks Equity Research
LabCorp's (LH) agreement to offer Interpace Diagnostics' molecular tests, ThyGenX and ThyraMIR gets renewed and extended for another two years.
Veeva (VEEV) to Gain Through Subscription Revenue Focus
by Zacks Equity Research
Veeva's (VEEV) strong sales growth will continue to be aided by focus on subscription revenue, better pricing and product innovation. However, higher costs remain a concern.
Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR
by Zacks Equity Research
Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR
Hill-Rom (HRC) Stock Down With Dull Patient Support Systems
by Zacks Equity Research
Hill-Rom's (HRC) Patient Support Systems revenue decreases due to the adverse effect of the WatchChild and Architectural Products divestitures along with lower rental revenues.
Here's Why Chemed (CHE) is a Suitable Growth Pick for Now
by Zacks Equity Research
Banking on favorable Net Margin and ROE, Chemed (CHE) stands out as one of the most suitable growth stocks.
Express Scripts to Boost Oral Medication With Diabetes Study
by Zacks Equity Research
Express Scripts' (ESRX) new study will support oral diabetes medication and reduce related costs.
IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.
5 Efficient Stocks to Buy for a Healthy Portfolio
by Tirthankar Chakraborty
Companies with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex (LMNX) has a broad range of products that are built on advanced technology. Also, it has collaborative agreements with several companies, which should help expand the use of its products.
Chemed (CHE) on Growth Track With VITAS & Roto-Rooter Arms
by Zacks Equity Research
The raised outlook for both Roto-Rooter unit and the bottom line indicate Chemed's (CHE) estimate of improved operating results in the upcoming quarters.
Illumina Teams Up With Telegraph Hill to Form Verogen
by Zacks Equity Research
Illumina (ILMC) and Telegraph Hill Partners plan to set up Verogen to accelerate adoption of NGS in the global forensic genomics market.
Is Amedisys (AMED) a Great Value Stock for Your Portfolio?
by Zacks Equity Research
Banking on a number of favorable metrics, Amedisys (AMED) stands out as one of the most suitable value stock.
Here's Why Masimo (MASI) is a Suitable Value Pick for Now
by Zacks Equity Research
Masimo (MASI) seems to be a solid value pick with favorable P/E ratio and P/FCF ratio compared with its broader industry.
LabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track
by Zacks Equity Research
LabCorp's (LH) decision to buy the analytical testing services arm of ChromaDex should fortify its Covance Food Solutions business.
Thermo Fisher's Patheon Buyout Gains Antitrust Clearance
by Zacks Equity Research
Thermo Fisher (TMO) gets antitrust clearance to move a step closer toward completion of Patheon acquisition.
Medtronic's (MDT) CE Mark in Heart Lead Strengthens CVG Arm
by Zacks Equity Research
Medtronic's (MDT) CVG arm continues to be the highest revenue grossing segment. Thus, the company's CE Mark receipt for Attain Stability Quad MRI SureScan Active-Fixation heart lead buoys optimism.
Ecolab Sales Solid Amid Escalating Delivered Product Costs
by Zacks Equity Research
Ecolab's (ECL) strong sales growth will continue to be aided by new business gains, better pricing and product innovation. However, higher delivered product costs remain a concern.
Bruker Launches D8 VENTURE BIOTOOLS for Home Laboratory
by Zacks Equity Research
Bruker's (BRKR) D8 VENTURE BIOTOOLS for laboratory macromolecular crystallography has some latest features in terms of source, detector and sample handling technology.
Omnicell (OMCL) Gains on Product Launches, Competition Rife
by Zacks Equity Research
Omnicell (OMCL) launches AcuDose software on XT hardware which allows Aesynt customers to fully benefit from XT. The company also launches XT Series Automated Supply Dispensing system.
Here's Why Investors Should Buy Amedisys (AMED) Right Now
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Align Technology's Invisalign Sales Strong Amid Margin Woes
by Zacks Equity Research
Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.